脑蛋白水解物治疗急性特发性面神经麻痹随机对照研究  

Cerebrolysin injection in the treatment of acute idiopathic facial paralysis:a randomized controled trial.

作　　者：付睿[1] 戴威[1] 孟然[1] 赵星辉[1] 黄栋[1] 

机构地区：[1]首都医科大学附属北京世纪坛医院神经内科,北京100038

出　　处：《中国神经精神疾病杂志》2011年第5期295-297,共3页Chinese Journal of Nervous and Mental Diseases

摘　　要：目的评价脑蛋白水解物(施普善)治疗急性特发性面神经麻痹的疗效。方法 72例急性特发性面神经麻痹患者随机分为施普善组和对照组各36例,两组同时使用相同剂量的激素、B族维生素和能量合剂治疗,施普善组在常规治疗基础上加用施普善治疗。治疗后4周和3个月采用House-Brackmann面神经功能分级系统评分评价疗效。结果治疗后4周和3个月施普善组与对照组患者的痊愈率分别为61.1%×33.3%和75%×44.4%,总有效率分别为80.5%vs.50%和94.4%vs.72.2%,二组差异均有统计学意义(P<0.05)。对于House-Brackmann分级Ⅴ～Ⅵ级的重症患者施普善组的总有效率较对照组更高为82.4%和44.4%(P=0.035),差异有统计学意义。结论在常规治疗的基础上加用施普善治疗急性特发性面神经麻痹获得较好的疗效。Objective To evaluate the efficacy of Cerebrolysin injection on the acute idiopathic facial paralysis.Methods Seventy-two patients with acute idiopathic facial paralysis were randomly assigned to Cerebrolysin injection（n=36） and control groups（n=36）.Patients in Cerebrolysin injection group received cerebrolysin 20 ml per day for ten consecutive days.Both Cerebrolysin and control groups received prednisone,vitamin B and Adenosine Disodiu.House-Brackmann facial nerve grading system was used to evaluate the outcomes at 4 weeks and 3 months after Cerebrolysin administration.Results Complete recover rate（61.1% vs.33.3% and 75% vs.44.4%）and the overall effective rate（80.5% vs.50% and 94.4% vs.72.2%） were significantly higher in Cerebrolysin group than in control group at either 4 weeks or 3 months after treatment.The difference between Cerebrolysin group and control group was statistically significant.The overall effective rate for grade Ⅴand Ⅵ of House-Brackmann were significantly higher in Cerebrolysin group than in control group（82.4% vs 44.4%）（P=0.035）.Conclusions Cerebrolysin is more effective than conventional treatment in treating acute idiopathic facial paralysis.

关 键 词：急性特发性面神经麻痹 施普善 House-Brackmann分级法 

分 类 号：R745.12[医药卫生—神经病学与精神病学]